Solid tumor therapy Inhibition of mechanostransduction as a novel therapy in the treatment of solid tumors

  • Edition: 2016
  • Research center: Institut de Bioenginyeria de Catalunya
  • Scientific Area: Pharmacology
  • Business area: Therapeutic
  • Status: In development
  • Contact: rocacusachs@ub.edu

Development of a new line of cancer therapy with peptido-mimetic drugs able to block mechanotransduction. The interaction between cytoskeletal proteins has been shown to trigger the activation of an oncogene in response to increased tissue rigidity. Both increased rigidity and subsequent oncogene activation are prevalent features in the majority of solid tumors. Thus, inhibiting oncogene activation in response to increased stiffness has a major potential to slow, halt or even revert tumor growth in a wide variety of cancer types.

Goals

  • To inhibit the interaction between cytoskeletal proteins to interfere with tumor progression. The antitumoral efficacy of peptido-mimetic drugs is going to be tested in diverse in vitro and in vivo settings in order to develop novel cancer therapies.
 

See project infographic:

Infographic

Problem to Solve

The proposed project aims to develop novel therapies for cancer treatments and to improve patient survival, overcoming current therapeutic resistance. In addition, the proposed therapy in development aims to be highly targeted and specific to minimize side effects.

Innovation

The development of peptido-mimetic drugs to specifically target mechanotransduction is a complete novel approach in cancer therapy. By inhibiting a specific interaction that only occurs in pathological and abnormal stiff tissues, the project aims to specifically block a malignant molecular event without affecting the surrounding tissue.

Level of Innovation

The solid tumor market is very mature and competitive, however the proposed approach has a novel mechanism of action that has not been explored in the past. The blocking of malignant responses triggered by tissue mechanics, independently of specific mutations or molecular signatures, represents an untapped approach with great potential to deliver novel and safe therapies.

Team

Supervisor. Leader of the cellular and molecular mechanobiology group

Pere Roca-Cusachs Soulere

Institut de Bioenginyeria de Catalunya

Group leader of the group in Resistance and progression in prostate cancer

Álvaro Aytés

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

Technology Transfer personnel

Dr. Diana González-Gironès

Institut de Bioenginyeria de Catalunya

Project Manager

Dr. Ester Rodríguez

Institut de Bioenginyeria de Catalunya

senior post-doctoral researcher

Dr. Alberto Elósegui

Institut de Bioenginyeria de Catalunya

Mentor

ICREA Research Professor and Co-founder

Roger Gomis

Inbiomotion SL

Partners

Obra Social
Caixa Capital Risc